Bevacizumab in Cervical Cancer: 5 Years After

Abstract

Over the past 5 years, addition of bevacizumab to combination chemotherapy for advanced, recurrent, and persistent cervical cancer has offered prolonged overall and progression-free survival. Since the original press release announcing the survival benefits of this antiangiogenesis therapy, there has been further study of bevacizumab related to quality of life, combination with other agents, use of imaging to evaluate likelihood of response, and development of biosimilars. This review summarizes publications related to bevacizumab use in advanced, recurrent, and persistent cervical cancer over the past 5 years since initial proof of concept of antiangiogenesis therapy and the initial dissemination of information regarding survival benefits of bevacizumab.

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

“…The standard treatment for recurrent or metastatic cervical cancer is a combination of chemotherapy and bevacizumab (159)(160)(161)(162), but treatment options for recurrent disease are limited. Almost all cervical cancers are mediated by human papillomavirus infection which, when considered alongside relatively high mutation burden and expression of PD-L1, FIGURE 3 | PFS, OS, and ORR in patients with NSCLC with or without baseline liver metastases.…”

Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer

“…Persistent human papillomavirus (HPV) infection, most commonly with HPV16, is a high-risk factor for CC 2 . Despite advances in surgical resection, chemoradiotherapy and anti-angiogenic therapy for CC, the long-term survival rate of CC patients remains unsatisfactory due to metastasis and recurrence 3 – 5 . Currently, cisplatin (DDP)-based concurrent chemoradiotherapy is the standard treatment for locally advanced CC 6 .…”

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma

“…This single trial led to regulatory approval of bevacizumab for cervical cancer in 60 countries on six continents. 51 The Moore criteria of five prognostic factors (performance status . 0, African American race, time to recurrence , 12 months, prior platinum, and pelvic disease) had been initially identified retrospectively and pooled with equal weight to predict response.…”